摘要
目的:膀胱过度活动症是发生在男、女性常见的慢性下泌尿道综合征,严重影响人群的生活质量,本文介绍其治疗药毒蕈碱受体阻断剂进展的侧面。方法:采用国内、外文献综述方法。结果与结论:选择性M3受体阻断剂作为膀胱过度活动症治疗药的一支奇葩,进展十分迅猛,对毒蕈碱受体有高度的选择性,标志一个新的里程开始,在改善膀胱过度活动症各项指标上,包括尿失禁、尿急迫、尿逼迫,在治疗膀胱过度活动症上展现了良好的前景。
ORJECTIVE:Symptomatic overactive bladder is a chronic lower urinary tract syndrome occurrence male and female, it impact on quality of population life to summarize the aspect of clinical application and progress on selectivity muscarine M3 receptor antagonists, evaluate the progress and clinical application of selectivity muscarine M3 receptor antagonists. METHODS:To collecte medical literatures in recent years at home and abroad. RESULTS & CONCLUTION:Selectivity muscarine M3 receptor antagonists has become the exotic flowes for therapeutic drug of Symptomatic overactive bladder, advance in selectivity muscarine M3 receptor antagonists has been swiftly in recent years, it has higher selectivity to muscarine M3 receptor,this indicates a new start of course of development,it tretment various index of symptomatic overactive bladder, urinary incontinence, urgecyof urination, precipitant urination,so selectivity muscarine M3 receptor antagonists plays an important roles in treatment of symptomatic overactive bladder.
出处
《中国医院用药评价与分析》
2007年第4期246-250,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
膀胱过度活动症
选择性毒蕈碱M
受体阻断剂
进展
评价
Symptomatic overactive bladder
Selectivity muscarine M3 receptor antagonists
Progress
Evaluation